90 likes | 369 Views
About Type 2 Diabetes<br>Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT.<br><br>Read Complete Report Here @ http://www.researchbeam.com/global-type-2-diabetes-therapeutics-2015-2019-market <br><br>Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019.<br><br>Enquire @ http://www.researchbeam.com/global-type-2-diabetes-therapeutics-2015-2019-market/enquire-about-report <br>
E N D
RESEARCH BEAM SIZE FORECAST RESEARCH Global Type 2 Diabetes Therapeutics Market 2015-2019 DEMAND AND SIZE MARKET AND & RESEARCH RESEARCH RESEARCH MARKET SIZE FORECAST RESEARCH DEMAND AND SIZE MARKET AND & RESEARCH RESEARCH • TELEPHONE: +1 (855) 711-1555E-MAIL:sales@researchbeam.com FORECAST
ReportOverview • About Type 2 Diabetes • Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT. • Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019. • To Get Complete Report Here @ http://www.researchbeam.com/global-type-2-diabetes-therapeutics-2015-2019-market
ReportOverview • Covered in this Report • This report covers the present scenario and the growth prospects of the Global Type 2 Diabetes Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of following drugs: • • DPP-4 inhibitors • • Biguanides • • Insulins • • GLP-1 receptor agonists • • Thiazolidenediones • • Sulfonulureas • • SGLT-2 inhibitors • • a-Glucosidase inhibitors • • Others (amylinomimetics, bile acid sequestrants, and dopamine receptor agonists) • Enquire @ http://www.researchbeam.com/global-type-2-diabetes-therapeutics-2015-2019-market/enquire-about-report
ReportOverview • Further, the territories considered in the report include: • • Americas (US, Brazil, and Mexico) • • 5EU (France, Germany, Italy, Spain, and UK) • • APAC (China, Japan, India, Russia, and other APAC countries) • Global Type 2 Diabetes Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Type 2 Diabetes Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. • Key Regions • • Americas • • APAC • • EMEA • Key Vendors • • AstraZeneca • • Novartis • • Novo Nordisk
ReportOverview • Other Prominent Vendors • • BoehringerIngelheim • • Bristol-Myers Squibb • • Eli Lilly • • Merck • • Sanofi • Market Driver • • Increased Awareness on Type 2 Diabetes • • For a full, detailed list, view our report • Market Challenge • • Poor Diagnosis Rate • • For a full, detailed list, view our report • Market Trend • • Focus on Emerging Markets • • For a full, detailed list, view our report
ReportOverview • Key Questions Answered in this Report • • What will the market size be in 2019 and what will the growth rate be? • • What are the key market trends? • • What is driving this market? • • What are the challenges to market growth? • • Who are the key vendors in this market space? • • What are the market opportunities and threats faced by the key vendors? • • What are the strengths and weaknesses of the key vendors?
Table Of Contents • 01. Executive Summary02. List of Abbreviations03. Scope of the Report • 04. Market Research Methodology05. Introduction06. Market Landscape7. WHO Diagnostic Criteria for Type 2 Diabetes08. Treatment Algorithm for Type 2 Diabetes by IDF09. Incidence and Prevalence10. Five Forces Analysis11. Market Segmentation by Drug Class
Table Of Contents • 12. Key Leading Countries13. Geographical Segmentation14. Buying Criteria15. Market Growth Drivers16. Drivers and their Impact17. Market Challenges18. Impact of Drivers and Challenges19. Market Trends20. Trends and their Impact21. Vendor Landscape • 22. Key Vendor Analysis • 23. Other Reports in this Series
Contact Visit us at : http://www.researchbeam.com/global-type-2-diabetes-therapeutics-2015-2019-market • TELEPHONE: +1 (855) 711-1555E-MAIL:help@researchbeam.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States